Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Location of broken bone in older people can have major impact on long-term health outcomes

In older individuals, the location of a broken bone can have significant impacts on long-term health outcomes, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

31 Mar 2020

Mobile health devices effective in reducing AF-related adverse events, study finds

A new study, published in the Journal of the American College of Cardiology, highlights the feasible use of mobile health (mHealth) devices to help with the screening and detection of a common heart condition.

31 Mar 2020

Two newer types of diabetes medications show heart and kidney benefits

Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

31 Mar 2020

Knowing the F.A.S.T. signs of stroke can help save lives

Stroke Foundation is reminding Australians it is vital to call triple zero (000) immediately if they suspect a stroke.

31 Mar 2020

Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome

Patients with acute coronary syndrome (ACS) who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for nine months had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

31 Mar 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the striking reductions in cardiovascular events and deaths seen among people taking 4 grams daily of the prescription fish oil, icosapent ethyl, according to findings from a REDUCE-IT substudy presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

30 Mar 2020

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure.

30 Mar 2020

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.

From AstraZeneca 30 Mar 2020

Taking ticagrelor alone better for patients with complex heart disease

Patients with complex heart disease who stopped taking aspirin three months after the insertion of one or more coronary stents and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor over the same period.

30 Mar 2020

Study quantifies economic burden of CVD in women with a history of preterm delivery

A new study quantifies the future economic burden of cardiovascular disease (CVD) in women with a history of preterm delivery.

30 Mar 2020

10-year follow-up study shows safety, efficacy of stenting compared with bypass surgery

In a study with the longest follow-up to date of patients with a high-risk form of heart disease known as left main coronary artery disease (LMCAD), researchers found no significant differences in rates of death, heart attack or stroke between patients who were treated with a stent and those who underwent heart bypass surgery.

30 Mar 2020

Trial confirms the effectiveness of TAVR strategy in a real-world setting

Patients who underwent transcatheter aortic valve replacement (TAVR) did not have a higher rate of death at one year compared with those who had their heart valve replaced via open-heart surgery, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

TAVR shows high rate of success and low risk of death in patients with bicuspid valve

Transcatheter aortic valve replacement procedures had a high rate of success and low risk of death or disabling stroke at 30 days in patients with a bicuspid, or two-leaflet, aortic valve, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Air pollution associated with dementia and cardiovascular disease

People continuously exposed to air pollution are at increased risk of dementia, especially if they also suffer from cardiovascular diseases, according to a study at Karolinska Institutet in Sweden published in the journal JAMA Neurology.

30 Mar 2020

Novel and fully automated technique can speed up detection of stroke

Human emotion system laboratory team at the University of Turku and Turku PET Centre, Finland, introduces a fully automated method for acute ischemic lesion segmentation on brain MRIs and shows how artificial intelligence can reduce the work load of radiologists.

30 Mar 2020

Renal denervation effective in patients with untreated high blood pressure

Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Extreme temperatures may double or triple deaths from cardiovascular disease

When temperatures reach extremes of an average daily temperature of 109 degrees Fahrenheit, the number of deaths from cardiovascular disease may double or triple.

30 Mar 2020

Stroke News and Research

Further Reading

Location of broken bone in older people can have major impact on long-term health outcomes

Mobile health devices effective in reducing AF-related adverse events, study finds

Two newer types of diabetes medications show heart and kidney benefits

Knowing the F.A.S.T. signs of stroke can help save lives

Ticagrelor therapy, without aspirin, can benefit patients with acute coronary syndrome

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Taking ticagrelor alone better for patients with complex heart disease

Study quantifies economic burden of CVD in women with a history of preterm delivery

10-year follow-up study shows safety, efficacy of stenting compared with bypass surgery

Trial confirms the effectiveness of TAVR strategy in a real-world setting

Treatment with ticagrelor alone reduces adverse events in patients with diabetes

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

TAVR shows high rate of success and low risk of death in patients with bicuspid valve

Air pollution associated with dementia and cardiovascular disease

Novel and fully automated technique can speed up detection of stroke

Renal denervation effective in patients with untreated high blood pressure

Extreme temperatures may double or triple deaths from cardiovascular disease

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News